Full Press Release Details
| FOR IMMEDIATE RELEASE | Contact: | Jim Mackaness | |
| Chief Financial Officer | |||
| 650 940-4700 |
Mountain View, California
IRIDEX Reports First Quarter 2008 Financial Results
IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter of
2008 ended March 29, 2008.
Revenue for the first quarter of 2008 was $11.5 million, an 8.7% decrease from the $12.6
million reported for the first quarter of 2007. The Company s net loss was $0.9 million or $0.10
per diluted share for the first quarter of 2008 compared with a net loss of $4.9 million or $0.61
per diluted share in the first quarter of 2007. The prior year financial results do include the
AMS/Laserscope aesthetics acquisition, which was completed on January 16, 2007.
Ophthalmology revenues were $7.5 million in the first quarter of 2008 compared with $7.2
million in 2007, an increase of 4.8%. Domestic ophthalmology revenues increased 10.6% to $4.4
million. International ophthalmology revenues decreased 2.4% to $3.1 million. Ophthalmology
recurring revenues, consisting of disposable products and service, represented 55.2% of our total
ophthalmology revenues for the first 3 months in 2008 and 55.5% for the comparable period in 2007.
Total aesthetics revenues were $3.9 million in the first quarter of 2008 compared with $5.4
million in the comparable period of 2007, a decrease of 26.8%. In the first quarter 2008 domestic
aesthetics revenues decreased $1.2 million to $1.5 million and international aesthetics revenues
decreased $0.3 million to $2.4 million.
Gross profit for the first quarter of 2008 was $4.8 million, compared with $5.2 million for
the first quarter of 2007. Gross margins were 41.9% and 41.5%, respectively. Operating expenses for
the first quarter 2008 were $5.5 million compared with $10.0 million for 2007.
Mr. Theodore A. Boutacoff, President and CEO stated, Operationally we are progressing towards
financial stability as demonstrated by the substantial reduction in our quarterly operating loss
from $4.9 million to $0.9 million primarily due to reductions in operating expenses. During the
first quarter we met our obligations with AMS by paying $1.7 million, leaving a balance related to
the Settlement Agreement of $3.1 million which we plan to fully satisfy by the end of our third
fiscal quarter. In addition, during the first quarter we successfully negotiated a new bank credit
facility with Wells Fargo Bank that replaced our previously existing credit agreements. The new
credit facility is an asset based revolving line that allows the Company to borrow up to $8
We continue to be encouraged by our improving ophthalmology revenues. The decrease in our
aesthetics revenues is primarily due to the difficulties incurred in the U.S. distribution channel
during 2007, which are still being experienced, coupled with the overall softening of the U.S.
aesthetics market. A focus in 2008 is to establish a productive US aesthetics sales channel.
Cash and cash equivalents were $4.0 million as of March 29, 2008 down from $5.8 million in
December 29, 2007 (this does not include $3.8 million in restricted cash). Inventories remained
constant at $16.0 million as of March 29, 2008 as compared to December 29, 2007. Accounts
receivable were $8.4 million as of March 29, 2008, compared to $8.9 million as of December 29,
IRIDEX management will conduct a conference call later today, Tuesday, May 13, 2008 at 5:00
p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing
(800) 240-7305 (U.S.) or (303) 262-2130 (International), or by visiting the Company s website at
www.iridex.com. A telephone replay will be available beginning on Tuesday, May 13, 2008 through
Tuesday, May 20, 2008 by dialing (800) 405-2236 (U.S.) or (303) 590-3000 (International) and
entering Passcode 11114278#. In addition, later today an archived version of the webcast will be
available on the Company s website at www.iridex.com.
IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems,
disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin
disorders in the aesthetics market. IRIDEX products are sold in the United States through a
direct sales force and internationally through a combination of a direct sales force and a
network of approximately 100 independent distributors into 107 countries. For further
information, visit the Company s website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of
1934, as amended, relating to the Company s financial stability, growth strategy and
prospects, ability to satisfy future financial obligations and continued improvement in our
ophthalmology revenues. Please see a detailed description of these and other risks
contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2007 and
our Quarterly Report on Form 10-Q for the first quarter ended March 29, 2008 filed with the
Securities and Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date and will not be updated.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
| Three Months Ended | ||||||||
| March 29, | March 31, | |||||||
| 2008 | 2007 | |||||||
| Sales | $ | 11,474 | $ | 12,566 | ||||
| Cost of sales | 6,669 | 7,357 | ||||||
| Gross profit | 4,805 | 5,209 | ||||||
| Operating expenses: | ||||||||
| Research and development | 1,025 | 1,729 | ||||||
| Sales, general and administrative | 4,518 | 8,274 | ||||||
| Total operating expenses | 5,543 | 10,003 | ||||||
| Loss from operations | (738 | ) | (4,794 | ) | ||||
| Interest and other (expense) income, net | (154 | ) | (126 | ) | ||||
| Loss before income taxes | (892 | ) | (4,920 | ) | ||||
| Provision for income taxes | ||||||||
| Net loss | $ | (892 | ) | $ | (4,920 | ) | ||
| Net loss per common share basic | $ | (0.10 | ) | $ | (0.61 | ) | ||
| Net loss per common share diluted | $ | (0.10 | ) | $ | (0.61 | ) | ||
| Shares used in per common share basic calculations | 8,824 | 8,080 | ||||||
| Shares used in per common share diluted calculations | 8,824 | 8,080 |
Condensed Consolidated Balance Sheets
| March 29, | December 29, | |||||||
| 2008 | 2007 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 4,013 | $ | 5,809 | ||||
| Restricted cash | 3,800 | |||||||
| Accounts receivable, net | 8,440 | 8,876 | ||||||
| Inventories, net | 16,013 | 15,967 | ||||||
| Prepaids and other current assets | 1,095 | 1,051 | ||||||
| Total current assets | 29,561 | 35,503 | ||||||
| Property and equipment, net | 1,481 | 1,621 | ||||||
| Goodwill | 3,239 | 3,239 | ||||||
| Other intangible assets, net | 5,358 | 5,944 | ||||||
| Other long term assets | 282 | 347 | ||||||
| Total assets | $ | 39,921 | $ | 46,654 | ||||
| Liabilities and Stockholders Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 4,404 | $ | 2,887 | ||||
| Bank line of credit | 5,281 | 4,863 | ||||||
| Accrued compensation | 1,567 | 2,024 | ||||||
| Accrued expenses | 6,005 | 7,809 | ||||||
| Accrued warranty | 1,500 | 1,895 | ||||||
| Deferred revenue | 3,254 | 3,350 | ||||||
| Bank term loan-current portion | 5,016 | |||||||
| Total liabilities | 22,011 | 27,844 | ||||||
| Commitments and contingencies (Note 10) | ||||||||
| Stockholders Equity: | ||||||||
| Convertible Preferred Stock, $.01 par value: | ||||||||
| Authorized: 2,000,000 shares; | ||||||||
| Issued and outstanding: 500,000 shares in 2008 and 2007 | 5 | 5 | ||||||
| Common Stock, $.01 par value: | ||||||||
| Authorized: 30,000,000 shares; | ||||||||
| Issued and outstanding: 8,824,301 shares in 2008 and 2007 | 89 | 89 | ||||||
| Additional paid-in capital | 38,727 | 38,695 | ||||||
| Accumulated other comprehensive loss | (128 | ) | (88 | ) | ||||
| Treasury stock, at cost | (430 | ) | (430 | ) | ||||
| (Accumulated deficit) retained earnings | (20,353 | ) | (19,461 | ) | ||||
| Total stockholders equity | 17,910 | 18,810 | ||||||
| Total liabilities and stockholders equity | $ | 39,921 | $ | 46,654 |